Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model

被引:68
作者
Bekkering, FC
Stalgis, C
McHutchison, JG
Brouwer, JT
Perelson, AS
机构
[1] Scripps Res Inst, Div Gastroenterol Hepatol 203N, La Jolla, CA 92037 USA
[2] Los Alamos Natl Lab, Los Alamos, NM USA
[3] Univ Rotterdam Hosp, Dept Hepatogastroenterol, Rotterdam, Netherlands
[4] Schering Plough Corp, Kenilworth, NJ USA
关键词
D O I
10.1053/jhep.2001.21552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients with hepatitis C virus (HCV) genotype 1 infection are resistant to standard interferon (IFN) therapy. We used a mathematical model to estimate the duration of daily therapy necessary to maximize the number of patients achieving viral negativity before 12 weeks of therapy. Patients from a study to determine HCV RNA reduction over 4 weeks using 3 million units (MU), 5 MU, or 10 MU of IFN alfa daily plus Ribavirin were compared with a group receiving IFN alfa 3 MU three times a week. By extending the linear regression and prediction interval lines, the estimated time to negativity was greater than 12 weeks for the standard IFN group, 42 to greater than 84 days for the 3 MU IFN daily plus Ribavirin, 39 to 60 days for 5 MU IFN daily plus Ribavirin and 25 to 45 days for the 10 MU IFN daily and Ribavirin group, respectively. Thus, the use of a predictive model based on log transformation and linear regression of the early HCV RNA response suggests daily doses of 5 or 10 million units of IFN plus Ribavirin will be theoretically necessary for longer than 4 weeks to maximize the number of patients who clear virus by 12 weeks of therapy. This model may be useful in predicting response in groups of patients receiving other therapies.
引用
收藏
页码:419 / 423
页数:5
相关论文
共 23 条
[1]   Epidemiology of hepatitis C [J].
Alter, MJ .
HEPATOLOGY, 1997, 26 (03) :S62-S65
[2]  
[Anonymous], 1997, HEPATOLOGY, V26, pS2
[3]  
Bekkering FC, 1997, HEPATOLOGY, V26, P1691
[4]   Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy [J].
Bekkering, FC ;
Brouwer, JT ;
Leroux-Roels, G ;
Van Vlierberghe, H ;
Elewaut, A ;
Schalm, SW .
JOURNAL OF HEPATOLOGY, 1998, 28 (06) :960-964
[5]   Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT [J].
Brouwer, JT ;
Hansen, BE ;
Niesters, HGM ;
Schalm, SW .
JOURNAL OF HEPATOLOGY, 1999, 30 (02) :192-198
[6]   Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C [J].
Davis, GL ;
Esteban-Mur, R ;
Rustgi, V ;
Hoefs, J ;
Gordon, SC ;
Trepo, C ;
Shiffman, ML ;
Zeuzem, S ;
Craxi, A ;
Ling, MH ;
Albrecht, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) :1493-1499
[7]  
Gretch DR, 1998, HEPATOLOGY, V28, p397A
[8]  
Herrmann E, 2000, ANTIVIR THER, V5, P85
[9]   DETECTION OF HEPATITIS-C VIRUS-RNA IN PATIENTS WITH CHRONIC HEPATITIS-C VIRUS-INFECTIONS DURING AND AFTER THERAPY WITH ALPHA INTERFERON [J].
KLETER, GEM ;
BROUWER, JT ;
HEIJTINK, RA ;
SCHALM, SW ;
QUINT, WGV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :595-597
[10]  
Lam NP, 1997, HEPATOLOGY, V26, P226